These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Chemoprevention of prostate cancer. Walsh PC N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287 [No Abstract] [Full Text] [Related]
9. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886 [TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R; J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831 [TBL] [Abstract][Full Text] [Related]
12. Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart? Garnick MB Harv Health Lett; 2012 Jan; 37(3):8. PubMed ID: 22400165 [No Abstract] [Full Text] [Related]
13. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428 [TBL] [Abstract][Full Text] [Related]
14. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Kaplan SA J Urol; 2005 Nov; 174(5):1904-5. PubMed ID: 16217336 [No Abstract] [Full Text] [Related]
15. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Svatek RS; Lotan Y Cancer Prev Res (Phila); 2011 Feb; 4(2):277-83. PubMed ID: 21163937 [TBL] [Abstract][Full Text] [Related]
16. [Comparison in the follow-up of two patients with persistent elevated PSA and negative prostate biopsy]. Sciarra A; Panebianco V Urologia; 2014; 81(1):60-3. PubMed ID: 24585440 [TBL] [Abstract][Full Text] [Related]
17. [Considerations about the value of prostate specific antigen in patients treated with 5-α reductase]. Brenes Bermúdez FJ Semergen; 2013 Mar; 39(2):118. PubMed ID: 23452542 [No Abstract] [Full Text] [Related]
19. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145 [TBL] [Abstract][Full Text] [Related]
20. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]